Print Page    E-mail Page    RSS    E-mail Alerts 

Investors

Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary and cardiac diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.

...
more >
Stock Quotemore >
C
$1.45
 Stock is Down 0.07 (4.61%)
Bellerophon (Nasdaq: BLPH)
Data as of 04/28/17 4:00 p.m. ET
Minimum 20 minute delay
Recent Newsmore >
04/07/17
Clinical Data on INOpulse® Presented at 37th Annual Meeting for the International Society for Heart and Lung Transplantation (ISHLT)
Clinical Data Presented From an Investigator Led Study of INOpulse in PAH Patients at Western University, London, Ontario and Allegheny General Hospital, Pittsburgh, PA Study Reinforces Hemodynamic Benefits of Pulsed iNO With Exercise WARREN, N.J., April 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today released clinical data from a poster presented at the 37th Annual Meeting for the International Society for Heart and ... 
03/27/17
Bellerophon Announces Poster Presentation on INOpulse® at 37th Annual Meeting for the International Society for Heart and Lung Transplantation
WARREN, N.J., March 27, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced a poster presentation at the 37th Annual Meeting for the International Society for Heart and Lung Transplantation (ISHLT) which will take place in San Diego, CA, from April 5 to 8.  The poster will feature data from an investigator-led study of INOpulse® in patients with pulmonary arterial hypertension (PAH). Title:   Ef... 
03/13/17
Bellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update
WARREN, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2016. “I am pleased with the progress in our ongoing clinical programs to treat pulmonary hypertension in unmet or under-served chronic pulmonary disease areas,” stated Fabian Tenenbaum, Chief Executive Officer of Bellerophon Therapeutics. ... 
Upcoming Eventsmore >
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources